Current status of risk stratification methods in acute coronary syndromes

Raphael See, James A de Lemos

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Distinguishing which patients with chest pain are at high risk versus which are at low risk remains an important clinical problem despite modern risk stratification strategies. Current approaches often over-utilize hospital resources, yet still miss a significant number of true acute coronary syndromes (ACS). This review focuses on important developments in risk stratification in ACS from 2004 through 2005. Risk models have been developed that use readily available patient characteristics, and head to head comparisons of the various models have been performed to guide clinicians in selecting between the different options. The most powerful models now include measurement of renal function, which has emerged as an important marker of risk. In addition to cardiac troponins, B-type natriuretic peptide (BNP) clearly augments risk prediction, and in the past year serial BNP measurement after discharge has shown promise as a simple way to monitor patient risk following ACS. Newer biomarkers are on the horizon but have not yet established their clinical value. Finally, advances in coronary CT angiography and bedside echocardiography offer hope that noninvasive imaging may play a more important role in early risk stratification in the near future.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalCurrent Cardiology Reports
Volume8
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Acute Coronary Syndrome
Brain Natriuretic Peptide
Troponin
Coronary Angiography
Chest Pain
Echocardiography
Biomarkers
Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current status of risk stratification methods in acute coronary syndromes. / See, Raphael; de Lemos, James A.

In: Current Cardiology Reports, Vol. 8, No. 4, 07.2006, p. 282-288.

Research output: Contribution to journalArticle

@article{f12783b94a8d447f9e6ac0f8de37fa51,
title = "Current status of risk stratification methods in acute coronary syndromes",
abstract = "Distinguishing which patients with chest pain are at high risk versus which are at low risk remains an important clinical problem despite modern risk stratification strategies. Current approaches often over-utilize hospital resources, yet still miss a significant number of true acute coronary syndromes (ACS). This review focuses on important developments in risk stratification in ACS from 2004 through 2005. Risk models have been developed that use readily available patient characteristics, and head to head comparisons of the various models have been performed to guide clinicians in selecting between the different options. The most powerful models now include measurement of renal function, which has emerged as an important marker of risk. In addition to cardiac troponins, B-type natriuretic peptide (BNP) clearly augments risk prediction, and in the past year serial BNP measurement after discharge has shown promise as a simple way to monitor patient risk following ACS. Newer biomarkers are on the horizon but have not yet established their clinical value. Finally, advances in coronary CT angiography and bedside echocardiography offer hope that noninvasive imaging may play a more important role in early risk stratification in the near future.",
author = "Raphael See and {de Lemos}, {James A}",
year = "2006",
month = "7",
doi = "10.1007/s11886-006-0060-8",
language = "English (US)",
volume = "8",
pages = "282--288",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Current status of risk stratification methods in acute coronary syndromes

AU - See, Raphael

AU - de Lemos, James A

PY - 2006/7

Y1 - 2006/7

N2 - Distinguishing which patients with chest pain are at high risk versus which are at low risk remains an important clinical problem despite modern risk stratification strategies. Current approaches often over-utilize hospital resources, yet still miss a significant number of true acute coronary syndromes (ACS). This review focuses on important developments in risk stratification in ACS from 2004 through 2005. Risk models have been developed that use readily available patient characteristics, and head to head comparisons of the various models have been performed to guide clinicians in selecting between the different options. The most powerful models now include measurement of renal function, which has emerged as an important marker of risk. In addition to cardiac troponins, B-type natriuretic peptide (BNP) clearly augments risk prediction, and in the past year serial BNP measurement after discharge has shown promise as a simple way to monitor patient risk following ACS. Newer biomarkers are on the horizon but have not yet established their clinical value. Finally, advances in coronary CT angiography and bedside echocardiography offer hope that noninvasive imaging may play a more important role in early risk stratification in the near future.

AB - Distinguishing which patients with chest pain are at high risk versus which are at low risk remains an important clinical problem despite modern risk stratification strategies. Current approaches often over-utilize hospital resources, yet still miss a significant number of true acute coronary syndromes (ACS). This review focuses on important developments in risk stratification in ACS from 2004 through 2005. Risk models have been developed that use readily available patient characteristics, and head to head comparisons of the various models have been performed to guide clinicians in selecting between the different options. The most powerful models now include measurement of renal function, which has emerged as an important marker of risk. In addition to cardiac troponins, B-type natriuretic peptide (BNP) clearly augments risk prediction, and in the past year serial BNP measurement after discharge has shown promise as a simple way to monitor patient risk following ACS. Newer biomarkers are on the horizon but have not yet established their clinical value. Finally, advances in coronary CT angiography and bedside echocardiography offer hope that noninvasive imaging may play a more important role in early risk stratification in the near future.

UR - http://www.scopus.com/inward/record.url?scp=33745874372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745874372&partnerID=8YFLogxK

U2 - 10.1007/s11886-006-0060-8

DO - 10.1007/s11886-006-0060-8

M3 - Article

C2 - 16822363

AN - SCOPUS:33745874372

VL - 8

SP - 282

EP - 288

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

ER -